OS Therapies (NYSE:OSTX) Trading 35.3% Higher – Should You Buy?

Shares of OS Therapies Inc (NYSE:OSTX) rose 35.3% during trading on Tuesday . The stock traded as high as $6.48 and last traded at $4.71. Approximately 668,717 shares changed hands during trading, an increase of 408% from the average daily volume of 131,554 shares. The stock had previously closed at $3.48.

Analyst Ratings Changes

Several research analysts recently weighed in on OSTX shares. Brookline Capital Management raised OS Therapies to a “strong-buy” rating in a research report on Thursday, August 22nd. Maxim Group began coverage on shares of OS Therapies in a report on Tuesday, November 26th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, EF Hutton Acquisition Co. I upgraded shares of OS Therapies to a “strong-buy” rating in a research note on Tuesday, September 3rd.

OS Therapies Stock Performance

The business has a fifty day simple moving average of $2.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC bought a new stake in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.